胸段食管癌术后淋巴结转移情况及其对患者5年生存期的影响研究

A Study on the Lymph Node Metastasis of Thoracic Esophageal Carcinoma and Its Effect on the Survival of 5 years

目的:探讨胸段食管癌术后淋巴结转移情况及其对患者5年生存期的影响。方法:对125例胸段食管癌患者的病例资料进行回顾性研究,统计其淋巴结转移情况以及转移度、转移数、转移域数等相关数据资料,并分析各种淋巴结转移情况对患者5年生存期的影响,再对基于不同淋巴结转移情况"手术组"与"手术+放疗组"的5年生存率进行比较。结果:有无淋巴结转移、淋巴结转移度、淋巴结转移数以及淋巴结转移域数均对胸段食管癌患者的5年生存率有显著影响(P<0.01);有淋巴结转移患者手术组的5年生存率显著低于手术+放疗组(P<0.01),同时术后加行放疗治疗对转移度>0、≤20%及转移数≥2枚的患者的5年生存率有显著影响(P<0.01)。结论:淋巴结转移是胸段食管癌患者术后效果的重要影响因素,淋巴结转移数0、1、及≥2枚的三级别分类或可更准确地反应胸段食管癌患者淋巴结转移数与5年生存率的关系;术后预防性放疗能提高有淋巴结转移、转移>0、≤20%及转移数≥2枚的患者的5年生存率。

Objective： To investigate the lymph node metastasis of thoracic esophageal carcinoma and its effect on the survival of 5 years. Methods： Data of 125 patients with thoracic esophageal carcinoma were retrospectively studied. The data of the patients with lymph node metastasis, metastasis, metastasis and metastasis were investigated. The effect of different lymph node metastasis on 5 year survival was investigated. Results： The lymph node metastasis, lymph node metastasis, lymph node metastasis and lymph node metastasis were the domain of thoracic esophageal cancer patients 5 years survival rate had significant effect （P〈0.01）; lymph node metastasis 5 year survival rate of patients were significantly lower than those of surgery plus radiotherapy group （P〈0.01） and received radiotherapy treatment on postoperative metastasis of 〉0 at the same time, less than 20% and more than 2 pieces of transfer number of patients 5 year survival rate had significant effect （P〈0.01）. Conclusion： Lymph node metastasis is an important factor for thoracic esophageal cancer patients after operation effect, the number of lymph node metastasis in 0, 1, and over three level classification of 2 pieces or more accurately the response of lymph node metastasis in patients with thoracic esophageal carcinoma and 5 year survival rate of the relationship; postoperative prophylactic radiotherapy improve the lymph node metastasis and metastasis of 〉0, the 5 year survival rate is less than 20% and more than 2 pieces of the number of metastatic patients.